Aandeel 1061 ESSEX BIO-TECHNOLOGY LIMITED
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Essex Bio-Technology Limited

Aandelen

1061

KYG312371035

Vertraagde tijd Hong Kong S.E.
Andere beurzen
 10:08:17 07-05-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
2,48 HKD -0,80% Intraday-grafiek van Essex Bio-Technology Limited +7,83% -0,40%
18/03 Essex Bio-Technology Limited rapporteert resultaten voor het volledige jaar eindigend op 31 december 2023 CI
2023 Essex Bio-Technology Limited rapporteert resultaten voor het halfjaar dat eindigde op 30 juni 2023 CI

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Essex Bio-Technology's 2023 Profit Jumps 22% on Higher Turnover
Essex Bio-Technology Posts Sound 2023 Annual Financial Results, Revenue Up 29.5%, Profit Up 22.1%
Essex Bio-Technology Limited Proposes Final Ordinary Dividend for the Financial Year Ended 31 December 2023, Payable June 17, 2024
Essex Bio-Technology Limited Reports Earnings Results for the Full Year Ended December 31, 2023
Essex Bio-Technology Limited Announces Change of Address of Head Office And principal Place of Business in Hong Kong
Essex Bio-Technology Limited(SEHK:1061) dropped from S&P Global BMI Index
Essex Bio-Technology's Profit Jumps 22% in H1
Essex Bio-Technology Posts Sound 2023 Interim Financial Results, Revenue Up 37.1%, Profit Up 22%
Essex Bio-Technology Limited Declares Interim Dividend for the Six Months Ended June 30, 2023, Payable on September 13, 2023
Essex Bio-Technology Limited Reports Earnings Results for the Half Year Ended June 30, 2023
Essex Bio-Technology's Ophthalmic Injection Showed Safety, Efficacy in Trial
The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed
Essex Bio-Technology Limited Provides Update on the Phase 1/2 Clinical Study in Relation to the Co-Development of the Licensed Product with Henlius for the Treatment of Exudative Age-Related Macular Degeneration
Essex Bio-Technology Limited Announces Early Repayment of Loan Facility
Essex Bio-Technology Limited commences an Equity Buyback Plan for 57,064,900 shares, representing 10% of its issued share capital, under the authorization approved on June 9, 2023.
Essex Bio-Technology Limited Announces Director Changes
Essex Bio-Technology Limited Declares Final Dividend for the Year Ended 31 December 2022
Essex Bio-Technology Limited's Equity Buyback announced on May 12, 2022 has expired.
Essex and Osteopore Entered into Exclusive Distribution Agreement
Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 1061
  4. Nieuws Essex Bio-Technology Limited
  5. Andere talen